Search alternatives:
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
significant amount » significant impact (Expand Search)
amount decrease » point decrease (Expand Search)
reported case » reported cases (Expand Search), reported use (Expand Search), imported cases (Expand Search)
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
significant amount » significant impact (Expand Search)
amount decrease » point decrease (Expand Search)
reported case » reported cases (Expand Search), reported use (Expand Search), imported cases (Expand Search)
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
Trends in the amount and proportion of dental materials for restoration in Japan.
Published 2023Subjects: -
70
-
71
-
72
-
73
-
74
DataSheet_2_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.pdf
Published 2022“…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”
-
75
DataSheet_3_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.csv
Published 2022“…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”
-
76
DataSheet_1_Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.pdf
Published 2022“…Currently, chemotherapy is the most used treatment; however, it has a poor median progression-free survival (mPFS) of no more than five months in the second-line setting. We report a case with DA that responded well to the immune checkpoint inhibitor (ICI) tislelizumab plus irinotecan in the second-line treatment. …”
-
77
Annual number of reported DILI and Non-DILI cases associated with statins in FAERS.
Published 2025Subjects: -
78
-
79
-
80